Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anaplastic Astrocytoma: early-phase trial registry
13 of 31 indexed Anaplastic Astrocytoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 13 currently recruiting · #495 of 28,707 conditions by registered trial count
Anaplastic Astrocytoma: 31 US clinical trials tracked, 13 recruiting.
Anaplastic Astrocytoma is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition anaplastic-astrocytoma
OPEN 13 | RECR 42% | LATE 1 | EARLY 27 | RANK #495 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Polycystic Ovary Syndrome (42% recruiting · 31 trials)
Anaplastic Astrocytoma lists 13 open slots (42% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Anaplastic Astrocytoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Anaplastic Astrocytoma is recruiting above its size-band peers.
13 of 31 indexed trials (41.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Anaplastic Astrocytoma research.
National Cancer Institute (NCI) accounts for 5 of 31 trials (16.1%). 22 distinct sponsors appear on at least one study for this condition label.
-
Most Anaplastic Astrocytoma trials plan to enrol fewer than 100 people.
Median target enrolment is 33 among the 31 trials that report a genuine target (sentinel values excluded). 25 of those (80.6%) plan for fewer than 100 participants.
-
Anaplastic Astrocytoma research is mostly interventional.
29 interventional and 2 observational studies make up this index (93.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
NCT05839379
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
NCT05843253
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
NCT04541082
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
The Methodist Hospital Research Institute
NCT03603405
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Northwell Health
NCT01269853
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
NCT02800486
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
Ashish Shah
NCT06264388
Loupe-Based Intraoperative Fluorescence Imaging
Guoqiang Yu
NCT04780009
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
NCT05084430
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
NCT05698524
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
NCT05956821
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
Columbia University
NCT06108206
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
NCT06333899
Pediatric Long-Term Follow-up and Rollover Study
Novartis Pharmaceuticals
NCT03975829
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
NCT03180502
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
NCT03919071
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
NCT03581292
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
NCT04978727
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
NCT00995007
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Katy Peters
NCT00610571
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Duke University
NCT00612651
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Julie Krystal
NCT01837862
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
NCT00606008
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
NCT02101905
AZD8055 for Adults With Recurrent Gliomas
National Cancer Institute (NCI)
NCT01316809
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Children's Hospital Medical Center, Cincinnati
NCT03355794
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
Northwell Health
NCT01238237
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Biogen
NCT00031083
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Northwell Health
NCT00301418
Cellular Immunotherapy Study for Brain Cancer
Jonsson Comprehensive Cancer Center
NCT01144247
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center
NCT01082926
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Anaplastic Astrocytoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Anaplastic Astrocytoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Anaplastic Astrocytoma page
31 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Anaplastic Astrocytoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Anaplastic Astrocytoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anaplastic Astrocytoma condition card totals 31 registered trials; most-linked intervention Temozolomide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.